The clinical efficacy of CsCl high pH metabolic therapy is best demonstrated by a recent case of primary liver
cancer (not included in the 50 cases reported in this study). The patient was a 39 year old female teacher who
was terminal. She was brought on a stretcher on April 25, 1984 with a large liver tumor extending
approximately 3 cm below the umbilical level.
The treatment was then immediately instituted. This consisted of administration of CsCl, ß-carotin, vitamin C,
Zn, Se, Mn, Cr and K salts by the oral route in addition to a concomitant massive IV doses of ascorbate, K, Mg,
Zn, Cn, Mn, Cr salts, B-complex vitamins, folic acid, DMSO and heparin.
After five consecutive treatment regimens EDTA was introduced to the therapy and the minerals present in the
IV solution were discontinued. On May 10, 1984, the patient was discharged, returned home walking without
assistance and displaying a pleasant smile on her face. The liver tumor had shrunk to five cm above the
umbilicus. The determination of alphafetoprotein (AFP), a specific marker for liver cancer, rare embronal
cancer and teratomas, decreased from unusual high value of 39,000 units, compared to normal levels of 13
units, measured before initiation of Cs-therapy, to 5,000 units obtained on last day of treatment.
The mechanism of action of Cs in cancer has been little studied. Both Cs+ and Rb+ can specifically enter the
cancer cells and embryonic cells, but not normal adult cells as has been demonstrated by Brewer. The cancer
cells contain high amounts of hydrogen ions rendering them acidic and they also contain higher Na+ levels
than found in normal cells.
If Cs+ or Rb+ can enter the cancer cells then the pH increases from as low as 5.5 to over pH 7.0. At a pH of
7.6, the cancer cell division will stop. At a pH of 8.0 to 8.5 the life span of the cancer cell is considerably
shortened (only hours).
In one case, the author has observed the shrinkage of metastases of breast cancer one hour after
Cs-treatment. Two days later, wrinkles of the skin appeared where the tumor was present. In another case of a
colon cancer with massive metastasis, massive infiltration of the abdominal wall, liver and other tissues,
seemed to have been reduced within 24 hours and continuing rapidly until the demise of the patient on the
fourteenth day of the Cs-treatment.
The uric acid levels measured at the onset of treatment was approximately 3.5 units which was increased to
over twenty units suggesting massive breakdowns of DNA, which produces the uric acid output. Therefore,
destruction of nuclear acids, as reflected by a significant rise in the uric acid, may be used as a predictive
measurement for treatment outcome. The failure of uric acid elevation may be indicative of lack of
destruction of cancer cells. This has proven to be a very consistent finding in our clinic.
There are certain factors which may enhance the Cs-therapy. The Cs-penetration into the cancer cell can
be increased by the following three methods:
1. The first approach resides in broadening the electron donor capacity of the cancer cell membrane by
the application of cyanide, an electron donor radical as found in nitriles (amygdalin, Laetrile, mandelontrile,
prunasin, ficin, cassivin), by selenium oxide, an electron donor radical, or by the use of DMSO.
2. The second approach enhances the potential gradient across the cancer cell membrane by the utilization
of weak acids like ascorbic acid (Vitamin C) and retinoic acid (Vitamin A).
3. The third method attempts to improve the circulation to the tumor and facilitate the destruction of
cross-linkages in the mucoid and birinous substances around the cancer cell. This can be achieved by
chelation therapy, i.e., the use of EDTA as has been shown by Blumer, who reported on the reduction of
cancer incidence by 90% by chelating patients (an average of 15 chelations in eight years). This approach
also reduced cardiovascular disease by 50%. Other chelating agents can be also used. Moreover, the use of
ß-carotene will lead to decomposition of blocking mucoid proteins mediated by electrical charges; also,
heparin, which acts through electrical charges, will inactivate the immune repelling and immune binding
capacities of the blocking mucoid proteins. These approaches will hinder cancer growth and they are
virtually atoxic.
cancer (not included in the 50 cases reported in this study). The patient was a 39 year old female teacher who
was terminal. She was brought on a stretcher on April 25, 1984 with a large liver tumor extending
approximately 3 cm below the umbilical level.
The treatment was then immediately instituted. This consisted of administration of CsCl, ß-carotin, vitamin C,
Zn, Se, Mn, Cr and K salts by the oral route in addition to a concomitant massive IV doses of ascorbate, K, Mg,
Zn, Cn, Mn, Cr salts, B-complex vitamins, folic acid, DMSO and heparin.
After five consecutive treatment regimens EDTA was introduced to the therapy and the minerals present in the
IV solution were discontinued. On May 10, 1984, the patient was discharged, returned home walking without
assistance and displaying a pleasant smile on her face. The liver tumor had shrunk to five cm above the
umbilicus. The determination of alphafetoprotein (AFP), a specific marker for liver cancer, rare embronal
cancer and teratomas, decreased from unusual high value of 39,000 units, compared to normal levels of 13
units, measured before initiation of Cs-therapy, to 5,000 units obtained on last day of treatment.
The mechanism of action of Cs in cancer has been little studied. Both Cs+ and Rb+ can specifically enter the
cancer cells and embryonic cells, but not normal adult cells as has been demonstrated by Brewer. The cancer
cells contain high amounts of hydrogen ions rendering them acidic and they also contain higher Na+ levels
than found in normal cells.
If Cs+ or Rb+ can enter the cancer cells then the pH increases from as low as 5.5 to over pH 7.0. At a pH of
7.6, the cancer cell division will stop. At a pH of 8.0 to 8.5 the life span of the cancer cell is considerably
shortened (only hours).
In one case, the author has observed the shrinkage of metastases of breast cancer one hour after
Cs-treatment. Two days later, wrinkles of the skin appeared where the tumor was present. In another case of a
colon cancer with massive metastasis, massive infiltration of the abdominal wall, liver and other tissues,
seemed to have been reduced within 24 hours and continuing rapidly until the demise of the patient on the
fourteenth day of the Cs-treatment.
The uric acid levels measured at the onset of treatment was approximately 3.5 units which was increased to
over twenty units suggesting massive breakdowns of DNA, which produces the uric acid output. Therefore,
destruction of nuclear acids, as reflected by a significant rise in the uric acid, may be used as a predictive
measurement for treatment outcome. The failure of uric acid elevation may be indicative of lack of
destruction of cancer cells. This has proven to be a very consistent finding in our clinic.
There are certain factors which may enhance the Cs-therapy. The Cs-penetration into the cancer cell can
be increased by the following three methods:
1. The first approach resides in broadening the electron donor capacity of the cancer cell membrane by
the application of cyanide, an electron donor radical as found in nitriles (amygdalin, Laetrile, mandelontrile,
prunasin, ficin, cassivin), by selenium oxide, an electron donor radical, or by the use of DMSO.
2. The second approach enhances the potential gradient across the cancer cell membrane by the utilization
of weak acids like ascorbic acid (Vitamin C) and retinoic acid (Vitamin A).
3. The third method attempts to improve the circulation to the tumor and facilitate the destruction of
cross-linkages in the mucoid and birinous substances around the cancer cell. This can be achieved by
chelation therapy, i.e., the use of EDTA as has been shown by Blumer, who reported on the reduction of
cancer incidence by 90% by chelating patients (an average of 15 chelations in eight years). This approach
also reduced cardiovascular disease by 50%. Other chelating agents can be also used. Moreover, the use of
ß-carotene will lead to decomposition of blocking mucoid proteins mediated by electrical charges; also,
heparin, which acts through electrical charges, will inactivate the immune repelling and immune binding
capacities of the blocking mucoid proteins. These approaches will hinder cancer growth and they are
virtually atoxic.
| Cesium therapy in cancer patients |
 | |  | |  | |  | |  | |  | |  | |  |